Seattle Genetics’ SeaGen Secure is a comprehensive reimbursement program providing personalized services to patients and helpful assistance for practices utilizing Adcetris (brentuximab vedotin) therapy (Table).
Adcetris is indicated for the treatment of patients with:
- Classical Hodgkin lymphoma after failure of autologous stem-cell transplantation (ASCT) or after failure of at least 2 multiagent chemotherapy regimens in patients who are not candidates for ASCT
- Classical Hodgkin lymphoma in patients at high risk for disease relapse or progression after autologous hematopoietic stem-cell transplantation
- Systemic anaplastic large-cell lymphoma after failure of at least 1 chemotherapy regimen
- Cutaneous T-cell lymphoma for patients who require systemic therapy.
SeaGen Secure Assistance Programs
The SeaGen Secure program is available to patients who are underinsured (with commercial or government-funded insurance) and to uninsured patients. SeaGen Secure assists in conducting a benefits investigation for each patient to determine their coverage.
Depending on their coverage status, patients may have 1 of the following options:
- Underinsured patients who need help with their coinsurance may be eligible for the SeaGen Secure Commercial Assistance Program or may be referred to an independent foundation for assistance
- For insured patients whose insurance does not cover Adcetris, SeaGen Secure will help with their claims appeal process. Patients whose appeal is rejected may be eligible for patient assistance
- Uninsured patients may be eligible for the SeaGen Secure Patient Assistance Program.
To be eligible for the SeaGen Secure Assistance Program, patients must:
- Permanently live in the United States
- Meet the income and diagnosis guidelines.
Application & Enrollment
To avail oneself of SeaGen Secure patient assistance and reimbursement support services, the Enrollment Form must first be completed (available at SeagenSecure.com). Enrollment forms can be submitted electronically via the website.
Completed forms can also be faxed to 855-557-2480 or e-mailed to CaseManager@SeagenSecure.com. Benefits investigation results will be faxed within 48 hours.
Prescribers are required to provide their information, provide the patient’s information and diagnosis, including an ICD-10 diagnosis code, indicate whether the patient has received a transplant and if the transplant was autologous or allogeneic, and indicate previous regimens that have been used. Patient information, including health insurance information, employer information, and gross annual family household income, must be provided.
SeaGen Secure connects patients and caregivers with an experienced Oncology Nurse Advocate.
The Oncology Nurse Advocate will provide support to help address patient concerns while they are receiving treatment, and will relay important patient information to your practice.
The Oncology Nurse Advocate will:
- Work with your patient to identify concerns before they become obstacles, and offer solutions to help address specific needs
- Provide ongoing support throughout the treatment experience
- Offer referrals to advocacy organizations for emotional support, transportation assistance, peer-to-peer connection programs, and resources for balancing work and cancer.
Patients will speak with the same Oncology Nurse Advocate every time they call SeaGen Secure.